Thrombotic risk determined by ABO, F8, and VWF variants in a population-based cohort study
- PMID: 40488174
- PMCID: PMC12145703
- DOI: 10.1016/j.rpth.2025.102875
Thrombotic risk determined by ABO, F8, and VWF variants in a population-based cohort study
Abstract
Background: Von Willebrand factor (VWF) and coagulation factor VIII (FVIII) plasma levels are associated with increased risk for venous thromboembolism (VTE).
Objectives: This study aimed to determine the thrombotic risk of rare and common variants of 27 genes linked to VWF or FVIII plasma levels in genome-wide association studies.
Methods: Exon sequences of 27 genes linked to plasma levels of VWF or FVIII in genome-wide association studies were analyzed for common and rare variants in 28,794 subjects without VTE (born during 1923-1950, 60% women), who participated in the Malmö Diet and Cancer study (1991-1996), with a follow-up time until 2018. Hazard ratios (HRs) were determined. P values were Bonferroni-corrected (P value = .05/27 <.0019). Common variants were analyzed individually. Rare qualifying variants (<0.1%) were collapsed.
Results: None of the 27 genes were associated with VTE in the rare variant collapsing analysis. Three common exon variants were significantly associated with VTE: rs8176719 (frameshift) in ABO (HR = 1.30; 95% CI, 1.20-1.42; P = 3.9 × 10-10), rs1800291 (p.Asp1260Glu) in F8 (HR = 1.29; 95% CI, 1.08-1.55; P = .00046 for men; HR = 1.17; 95% CI, 1.06-1.29; P = .00019 for women), and rs1063856 (p.Thr789Ala) in VWF (HR = 1.10; 95% CI, 1.04-1.17; P = .00057). A risk score of these 3 variants was dose-dependently associated with VTE (5 risk alleles): HR = 2.8; 95% CI, 1.7-4.7; and P value = .00008. The area under the curve for VTE in receiver operating characteristics for the risk score was similar to FV Leiden (0.55 vs 0.54).
Conclusion: The risk score of 3 common variants in VWF, F8, and AB0 genes is associated with VTE risk similar to FV Leiden.
Keywords: ABO blood-group system; factor VIII; molecular epidemiology; venous thromboembolism; von Willebrand factor.
© 2025 The Author(s).
Figures
References
-
- Dahlbäck B. Blood coagulation. Lancet. 2000;355:1627–1632. - PubMed
-
- Koster T., Blann A.D., Briët E., Vandenbroucke J.P., Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155. - PubMed
-
- Smith A., Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly study. Circulation. 2005;112:3080–3087. - PubMed
-
- Seaman C.D., Yabes J., Comer D.M., Ragni M.V. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J Thromb Haemost. 2015;13:1999–2003. - PubMed
-
- Rietveld I.M., Lijfering W.M., le Cessie S., Bos M.H.A., Rosendaal F.R., Reitsma P.H., Cannegieter S.C. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost. 2019;17:99–109. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
